Original Research

Published on 28 Jun 2024

Development and validation of the BMQ-AIR©: a screening tool for assessing patients’ treatment beliefs about switching to anti-inflammatory reliever (AIR) therapy

in Drugs Outcomes Research and Policies

Holly Foot
Amy Hai Yan Chan
Rob Horne

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1351851

Original Research

Published on 27 Jun 2024

Does China’s national volume-based drug procurement policy promote or hinder pharmaceutical innovation?

in Drugs Outcomes Research and Policies

Xiujuan Li
Jiachun Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1392239

107 views

Original Research

Accepted on 26 Jun 2024

Signal Mining and Analysis of Trifluridine/Tipiracil Adverse Events Based on Real-World Data from the FAERS Database

in Drugs Outcomes Research and Policies

Yongli Hu
Yan D
Zhisheng Qiu
Zhu Chenglou
wang junhong
Liang Tong
Tianxiang Liu
Da Mingxu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1399998

Original Research

Accepted on 26 Jun 2024

Management of Drug Supply Chain Information based on "Artificial Intelligence + Vendor Managed Inventory" in China: Perspective Based on a Case Study

in Drugs Outcomes Research and Policies

Jianwen Shen
Fengjiao Bu
Zhengqiang Ye
Min Zhang
Qin Ma
Jingchao Yan
Taomin Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1373642

Original Research

Published on 26 Jun 2024

Physicians’ perceptions and awareness of adverse effects of proton pump inhibitors and impact on prescribing patterns

in Drugs Outcomes Research and Policies

Abdelmoneim Awad
Abdulaziz Al-Tunaib
Sarah Al-Saraf

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1383698

Original Research

Accepted on 25 Jun 2024

Cost-effectiveness Analysis of Carelizumab plus Paclitaxel and Carboplatin versus Sintilimab plus Gemcitabine and Cisplatin or Carboplatin for the First-line Treatment of Local Advanced or Metastatic Squamous NSCLC in Chinese Mainland

in Drugs Outcomes Research and Policies

Xiaoting Liu
Xiao-Xue Liu
Wenqing Shao
Yi Zhou
Jing Zhang
Cuirong Zhao
Chengwu Shen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1356725

Original Research

Accepted on 25 Jun 2024

Risk of drug-induced angioedema: A pharmacovigilance study of FDA Adverse Event Reporting System database

in Drugs Outcomes Research and Policies

Maoxia Fan
Kaibin Niu
Xiaoqi Wu
Hongshuo Shi

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1417596

Original Research

Accepted on 24 Jun 2024

Identifying and presenting key country-specific indicators related to medication adherence: A comprehensive study across European countries

in Drugs Outcomes Research and Policies

Tamas Agh
Kristina Garuolienė
Anne Gerd Granas
João Gregório
Nilay Aksoy
Nataliia Khanyk
Maja Ortner Hadžiabdić
Przemyslaw Kardas

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1390629

Original Research

Accepted on 24 Jun 2024

The Value of Second-line Anti-HER2 Therapy in Metastatic HER-2 Positive Patients: A Cost-effectiveness Analysis in China

in Drugs Outcomes Research and Policies

Lu Li
Shilei Yang
Fengqi Fang
Li Tian
Ying He
Jia Li
Yanwei Chen
Deshi Dong

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1382120

Original Research

Published on 24 Jun 2024

Unraveling elements of value-based pricing from a pharmaceutical industry’s perspective: a scoping review

in Drugs Outcomes Research and Policies

Aniek Dane
Carin Uyl-de Groot
Hugo van der Kuy

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1298923

238 views

Original Research

Accepted on 21 Jun 2024

Preemptive oral analgesia with steroidal and nonsteroidal anti-inflammatory drugs in periodontal surgery: a systematic review

in Drugs Outcomes Research and Policies

Lívio Portela de Deus Lages
Cristiane De Cássia Bergamaschi
Luciane Cruz Lopes
Eduardo Gomes da Frota
Marcus Tolentino Silva
Thiago Lima Monte
Rogério Heládio Lopes Motta

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1385401

Original Research

Accepted on 21 Jun 2024

Cost-Effectiveness of Utidelone and Capecitabine versus Monotherapy in Anthracycline-and Taxane-Refractory Metastatic Breast Cancer

in Drugs Outcomes Research and Policies

Mulan Chen
Heng Zhang
Xiaoyan He
Yingtao Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1303808

Original Research

Published on 20 Jun 2024

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

in Drugs Outcomes Research and Policies

Gengwei Huo
Ying Song
Wei Liu
Hua Guo
Peng Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1391896

277 views

Original Research

Published on 19 Jun 2024

Implementation of risk-based lipid-lowering therapies in older (age ≥ 65 years) and very-old adults (age ≥ 75 years) with ischemic heart disease in the greater Salzburg region

in Drugs Outcomes Research and Policies

Kristen Kopp
Lukas J. Motloch
Bernhard Wernly
Alexander E. Berezin
Victoria Maringgele
Anna Dieplinger
Uta C. Hoppe
Michael Lichtenauer

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1357334

228 views

Original Research

Published on 19 Jun 2024

Understanding patient demand for and use of antibiotics for upper respiratory tract infection: A qualitative application of the Necessity-Concerns Framework in Saudi Arabia

in Drugs Outcomes Research and Policies

Nouf Almeshal
Holly Foot
Amy Louise Clarke
Amy Hai Yan Chan
Rob Horne

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1399698

184 views

Original Research

Accepted on 18 Jun 2024

Evaluating Drug Withdrawal Syndrome Risks through Food and Drug Administration Adverse Event Reporting System: A Comprehensive Disproportionality Analysis

in Drugs Outcomes Research and Policies

Zheng Zhang
Qianzhi Yang
Minghao Chen
Wah Yang
Yuping Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1385651

Navigation group

Articles

Development and validation of the BMQ-AIR©: a screening tool for assessing patients’ treatment beliefs about switching to anti-inflammatory reliever (AIR) therapy

Does China’s national volume-based drug procurement policy promote or hinder pharmaceutical innovation?

Signal Mining and Analysis of Trifluridine/Tipiracil Adverse Events Based on Real-World Data from the FAERS Database

Management of Drug Supply Chain Information based on "Artificial Intelligence + Vendor Managed Inventory" in China: Perspective Based on a Case Study

Physicians’ perceptions and awareness of adverse effects of proton pump inhibitors and impact on prescribing patterns

Cost-effectiveness Analysis of Carelizumab plus Paclitaxel and Carboplatin versus Sintilimab plus Gemcitabine and Cisplatin or Carboplatin for the First-line Treatment of Local Advanced or Metastatic Squamous NSCLC in Chinese Mainland

Risk of drug-induced angioedema: A pharmacovigilance study of FDA Adverse Event Reporting System database

Identifying and presenting key country-specific indicators related to medication adherence: A comprehensive study across European countries

The Value of Second-line Anti-HER2 Therapy in Metastatic HER-2 Positive Patients: A Cost-effectiveness Analysis in China

Unraveling elements of value-based pricing from a pharmaceutical industry’s perspective: a scoping review

Preemptive oral analgesia with steroidal and nonsteroidal anti-inflammatory drugs in periodontal surgery: a systematic review

Cost-Effectiveness of Utidelone and Capecitabine versus Monotherapy in Anthracycline-and Taxane-Refractory Metastatic Breast Cancer

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

Implementation of risk-based lipid-lowering therapies in older (age ≥ 65 years) and very-old adults (age ≥ 75 years) with ischemic heart disease in the greater Salzburg region

Understanding patient demand for and use of antibiotics for upper respiratory tract infection: A qualitative application of the Necessity-Concerns Framework in Saudi Arabia

Evaluating Drug Withdrawal Syndrome Risks through Food and Drug Administration Adverse Event Reporting System: A Comprehensive Disproportionality Analysis